<div id="readability-page-1"><p><span>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report)</span> had its price objective hoisted by HC Wainwright  from $62.00 to $65.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. HC Wainwright's price objective would indicate a potential upside of 129.02% from the company's previous close.</p><div><p><span></span><span>Get <strong>Agios Pharmaceuticals</strong> alerts:</span></p></div><p>A number of other equities research analysts have also recently commented on AGIO. The Goldman Sachs Group dropped their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, November 20th. Leerink Partners increased their price target on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, December 26th. JPMorgan Chase &amp; Co. upped their price objective on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, January 6th. Bank of America raised their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, December 24th. Finally, Truist Financial upped their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Hold&#34; and an average price target of $39.78.</p><p><b>Get Our Latest Stock Analysis on Agios Pharmaceuticals</b></p><h2>Agios Pharmaceuticals Stock Up 2.4%</h2><p>Shares of NASDAQ:AGIO traded up $0.67 during trading on Thursday, hitting $28.38. The stock had a trading volume of 471,346 shares, compared to its average volume of 925,984. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The stock has a 50-day simple moving average of $27.37 and a two-hundred day simple moving average of $34.17. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -4.05 and a beta of 0.91. </p><p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate of ($1.96) by $0.11. The business had revenue of $19.97 million for the quarter, compared to the consensus estimate of $12.06 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm's revenue for the quarter was up 86.9% compared to the same quarter last year.  As a group, sell-side analysts forecast that  Agios Pharmaceuticals will post -6.85 earnings per share for the current year. </p><h2>Insider Buying and Selling</h2><p>In other news, insider Sarah Gheuens sold 2,932 shares of the firm's stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the transaction, the insider directly owned 64,795 shares of the company's stock, valued at approximately $1,755,296.55. This trade represents a 4.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider James William Burns sold 2,932 shares of the firm's stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider directly owned 31,718 shares in the company, valued at $859,240.62. This trade represents a 8.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,303 shares of company stock worth $901,977 in the last ninety days. Company insiders own  4.30% of the company's stock. </p><h2>Institutional Trading of Agios Pharmaceuticals</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaCentric Advisors LLC purchased a new position in shares of  Agios Pharmaceuticals during the 4th quarter worth $358,000.  New York State Common Retirement Fund raised its stake in  Agios Pharmaceuticals by 3.9% during the fourth quarter. New York State Common Retirement Fund now owns 51,707 shares of the biopharmaceutical company's stock worth $1,407,000 after purchasing an additional 1,917 shares during the period.  Campbell &amp; CO Investment Adviser LLC purchased a new stake in shares of  Agios Pharmaceuticals during the 4th quarter valued at approximately $224,000.  Knott David M Jr acquired a new position in  Agios Pharmaceuticals in the fourth quarter valued at approximately $490,000.  Finally, Alps Advisors Inc. lifted its holdings in  Agios Pharmaceuticals by 73.8% in the fourth quarter. Alps Advisors Inc. now owns 47,881 shares of the biopharmaceutical company's stock valued at $1,303,000 after acquiring an additional 20,327 shares during the last quarter. </p><h2>About Agios Pharmaceuticals</h2> (Get Free Report)<p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.  </p><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p><h2>Read More</h2><ul><li>Five stocks we like better than Agios Pharmaceuticals</li><li>USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.</li><li>The DoD just got a new drone supplier</li><li>Think You Missed Silver? You’re Wrong. Here’s Why.</li><li>When to buy gold (mathematically)</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p><p>While Agios Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AGIO

<p>HC Wainwright has raised its target price for Agios Pharmaceuticals (NASDAQ:AGIO) from $62.00 to $65.00, maintaining a "buy" rating. This new target suggests a potential upside of 129.02% from the previous close. Other analysts have varied opinions, with Goldman Sachs lowering its target to $25.00 and maintaining a "neutral" rating, while others have set higher targets. Agios shares rose 2.4% to $28.38, with a market cap of $1.65 billion. The company reported a quarterly EPS of ($1.85), beating estimates, and revenue of $19.97 million, up 86.9% year-over-year.</p>

HC Wainwright Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price